Ten companies skyrocketed last week, jumping by double and triple digits, as investor sentiment was fueled by a flurry of corporate developments, strong earnings performance, and upbeat growth guidance.

Notably, two healthcare firms saw their share prices soar by more than 100 percent on news of acquisition and positive clinical trial results.

In this article, we spotlight the 10 top performers of the past trading week and detail the reasons behind their gains.

To come up with the list, we considered only the stocks with a $2 billion market capitalization and more than 5 million shares in trading volume, ranked based on their percentage change between November 7 and 14, 2025.

10. Sealed Air Corp. (NYSE:SEE)

Sealed Air saw its share prices jump by 18.09 percent week-on-week as investor sentiment was fueled by reports that it is set to be acquired by investment firm Clayton, Dubilier, and Rice (CD&R).

A report by the Wall Street Journal said Wednesday that the two companies are now underway negotiations for the potential merger which could see the split of Sealed Air Corp.’s (NYSE:SEE) food packaging and protective packaging businesses.

In other news, Sealed Air Corp. (NYSE:SEE) earlier this month announced a strong earnings performance in the third quarter of the year, having incurred a 109.4 percent jump in net profit at $186 million versus only $89 million in the same period last year, primarily driven by a $57 million special items income.

Net sales, however, ended flat at $1.3 billion as a 1 percent growth in the food packaging segment was offset by the 1 percent dip in the protective packaging unit. Volumes and prices also decreased by 1 percent during the period.

On December 19, common shareholders of Sealed Air Corp. (NYSE:SEE) as of December 5 record are set to receive 20 cents worth of dividends as part of the company’s quarterly dividend distribution.

9. Clearwater Analytics Holdings Inc. (NYSE:CWAN)

Clearwater surged by 18.97 percent week-on-week as investors snapped up shares following reports that it was considering a potential sale after receiving interest from prospective buyers.

According to a report by Bloomberg, citing sources privy to the matter, Clearwater Analytics Holdings Inc. (NYSE:CWAN) is now working with advisers to weigh its options and solicit interest from prospective buyers, which it later identified as Warburg Pincus and Permira.

Additionally, last week’s gains can be attributed to bargain-hunting after the company fell to a new record low, dampened by a dismal earnings performance in the third quarter of the year.

During the period, Clearwater Analytics Holdings Inc. (NYSE:CWAN) nosedived to a $10.3 million attributable net loss from a $3.6 million attributable net income in the same period last year.

Revenues, on the other hand, jumped by 77 percent to $205 million from $115.8 million in the same comparable period, beating its guidance of $203 million to $204 million.

For the full-year period, Clearwater Analytics Holdings Inc. (NYSE:CWAN) expects revenues to end at $730 million to $731 million, or an implied year-on-year growth of 62 percent.

In the fourth quarter alone, revenues are targeted at a range of $216 million to $217 million, or a year-on-year growth of 71 to 72 percent.

8. On Holding AG (NYSE:ON)

On Holding grew its share prices by 21.14 percent week-on-week as investor sentiment was boosted by a stellar earnings performance that sparked a higher growth outlook for the full-year period.

In its latest earnings call, On Holding AG (NYSE:ONON) said it was able to grow its net income by 290 percent to 118.9 million Swiss francs from only 30.5 million Swiss francs in the same period last year.

Net sales also jumped by 25 percent to 794.4 million Swiss francs from 635.8 million Swiss francs year-on-year, primarily driven by a strong performance in both direct-to-consumer and wholesale channels, which grew by 27.6 percent and 23.3 percent, respectively.

Following the results, On Holding AG (NYSE:ONON) said it now expects higher figures across key growth metrics. Net sales growth outlook was raised to 34 percent from 31 percent previously; gross profit margin was upgraded to 62.5 percent from 60.5 to 61 percent earlier; while adjusted EBITDA margin was projected to grow by 18 percent, versus 17 to 17.5 percent prior.

On Holding AG (NYSE:ONON) also raised its three-year CAGR outlook beginning in 2026 to 30 percent from 26 percent prior.

“Based on our current outlook for 2025. This isn’t just about exceeding targets. It’s a testament to the unparalleled momentum of our brand. The strength of our strategy and the incredible dedication of our entire team,” said CEO and CFO Martin Hoffman.

7. Ondas Holdings Inc. (NASDAQ:ONDS)

Ondas Holdings soared by 23.58 percent week-on-week as investors took heart from an investment firm’s bullish outlook for the stock, while also cheering its stellar earnings performance in the third quarter of the year.

In its market note, investment firm Oppenheimer raised its rating for Ondas Holdings Inc. (NASDAQ:ONDS) to “outperform” from “perform” previously, while issuing a price target of $12 or an implied 67 percent upside potential from its closing price of $7.18 on Friday.

The upgrade followed Ondas Holdings Inc.’s (NASDAQ:ONDS) strong earnings performance for the periods July to September, having trimmed its net loss attributable to shareholders by 17.7 percent to $8.78 million from $10.67 million in the same period last year.

Meanwhile, revenues surged by 582 percent to $10.1 million from $1.48 million year-on-year, primarily driven by strong delivery volumes from Iron Drone and Optimus systems under its contracts with military and public safety customers, coupled with revenues from the recent Apeiro Motion acquisition.

On the flip side, adjusted EBITDA loss grew by 23 percent to $8.76 million from $7.1 million.

Looking ahead, Ondas Holdings Inc. (NASDAQ:ONDS) said it expects higher revenues of $36 million, as compared with $25 million previously, reflecting the continued strong performance of the core OAS business as well as the addition of newly acquired businesses since the beginning of the second quarter of 2025.

6. Opendoor Technologies Inc. (NASDAQ:OPEN)

Opendoor Technologies climbed by 23.78 percent week-on-week despite suffering from losses in the last two trading days, primarily driven by a $1 million insider buying ahead of a dividend distribution.

In a regulatory filing on Wednesday, Opendoor Technologies Inc. (NASDAQ:OPEN) said that its CEO Kasra Nejatian, acquired 125,000 common shares at a price of $8.0365 apiece for a total of $1.004 million, ahead of the November 18 record date for warrant dividends payable on November 21.

Under the terms, each investor holding 30 common shares of Opendoor Technologies Inc. (NASDAQ:OPEN) is set to receive one each of Series K, A, and Z warrants, exercisable at prices of $9, $13, and $17, respectively.

Subject to shareholder approval, the new securities will be listed on the stock exchange under the symbols OPENW, OPENL, and OPENZ.

However, the stock fell on Thursday and Friday as investors resorted to profit-taking, while digesting the potential dilution impact of the warrant dividends on existing shareholdings.

Also last week, Opendoor Technologies Inc. (NASDAQ:OPEN) announced that it widened its net loss by 15 percent to $90 million from $78 million in the same comparable period, amid a 37 percent lower gross profit.

Revenues, on the other hand, declined by 33 percent to $915 million from $1.377 billion in the same period last year, but exceeded its earlier guidance of $800 million to $875 million.

5. Baytex Energy Corp. (NYSE:BTE)

Baytex Energy jumped by 25.4 percent week-on-week after an eight-day rally boosted by an investment firm’s bullish rating and news that it was officially exiting the US market.

Earlier this week, Baytex Energy Corp. (NYSE:BTE) said that it signed a definitive agreement with an undisclosed buyer for the sale of its Eagle Ford assets for $2.305 billion.

“Monetizing our US Eagle Ford assets strengthens our balance sheet, supports capital allocation to our highest-return opportunities and positions us to deliver meaningful shareholder returns,” Baytex Energy Corp. (NYSE:BTE) President and CEO Eric Greager said.

The company added that the transaction would support its return to a net cash position, proceeds of which will be used to repay its outstanding credit facilities and notes due 2030.

The transaction is targeted to be completed by the end of the year or early next year, subject to closing conditions and regulatory approvals.

Following the news, Raymond James Financial issued an “outperform” rating on the stock, or higher than the “market perform” previously. It also raised its price target to C$5.50 from C$3.50 earlier.

Meanwhile, shareholders as of December 15 record would expect to receive  C$0.0225 worth of dividends on January 2, 2026. For US shareholders, the dividends would be equivalent to $0.0161 per share assuming a foreign exchange rate of C$1.40.

4. Avadel Pharmaceuticals plc (NASDAQ:AVDL)

Avadel jumped by 26.06 percent week-on-week as investors loaded up portfolios after receiving a new takeover interest from a new pharmaceutical giant.

Last Friday, Avadel Pharmaceuticals plc (NASDAQ:AVDL) soared to as much as $23.57—its highest price in more than a decade—before ending the day just up by 22.45 percent at $23.56 apiece, following announcements that it received a new acquisition interest from H Lundbeck A/S to buy its shares at a price of $23 apiece.

The total price was significantly higher than Alkermes’ bid of $20 apiece.

Under Lundbeck’s offer, it would acquire the shares for $21 in cash and non-transferrable contingent value rights (CVR) amounting to $2 upon the achievement of two annual sales milestones for Lumryz and valiloxybate.

Meanwhile, Alkermes sought to buy the shares for $18.50 per share, and a CVR of $1.50 contingent upon final approval of the Food and Drug Administration of Lumryz.

Despite a definitive agreement already signed between Avadel Pharmaceuticals plc (NASDAQ:AVDL) and Alkermes, the former said that its board of directors deemed Lundbeck’s proposal to be superior.

Avadel cannot break its agreement with Alkermes, but it is allowed to talk and share information with another prospective buyer.

3. Scholar Rock Holding Corp. (NASDAQ:SRRK)

Scholar Rock saw its share prices climb by 29.2 percent on week-on-week as investors took heart from positive developments for its drug candidate for spinal muscular atrophy (SMA).

In an announcement last week, Scholar Rock Holding Corp. (NASDAQ:SRRK) said that it sat down with the Food and Drug Administration and third-party manufacturing contractor, Catalent Indiana, last Wednesday to discuss its biologics license application for apitegromab.

This followed the FDA’s rejection of its application last September following inspection issues at the manufacturing facility.

Catalent, for its part, detailed progress in implementing the remediation plan, and affirmed that the facility would be ready for reinspection by the end of this year.

Scholar Rock Holding Corp. (NASDAQ:SRRK) said it plans to resubmit a BLA application, with official launch targeted by next year.

Additionally, it said that it targets to secure the approval of the European Medicines Agency (EMA) to sell apitegromab to Europe by mid 2026.

Also on Friday, the company announced the results of its earnings performance in the third quarter of the year, where it widened its net loss by 58 percent to $102 million from $64.5 million in the same period last year, pulled down by a 60 percent higher operating loss of $103.5 million versus $64.78 million year-on-year.

2. Cidara Therapeutics Inc. (NASDAQ:CDTX)

Cidara Therapeutics soared by more than 100 percent week-on-week, as investors repositioned portfolios following news that it is set to be acquired by Merck Co. for $9.2 billion.

On Friday alone, Cidara Therapeutics Inc. (NASDAQ:CDTX) climbed to as high as $218.85 before trimming gains to end the day just up by 105.41 percent at $217.71 apiece.

This followed news that Cidara Therapeutics Inc. (NASDAQ:CDTX) entered into a definitive agreement with Merck, under which the latter would acquire its shares at a price of $221.50 apiece, through its subsidiary.

The companies expect to close the transaction in the first quarter of 2026.

The acquisition followed Cidara Therapeutics, Inc. (NASDAQ:CDTX) receipt of a fast track designation from the Food and Drug Administration for its drug candidate, CD388, which aims to prevent influenza in individuals at higher risk of complications.

The CD388 is currently being evaluated in a Phase 3 study among adult and adolescent participants who are at higher risk of developing complications from influenza.

1. Cogent Biosciences, Inc. (NASDAQ:COGT)

Cogent Biosciences skyrocketed by 126.3 percent week-on-week, as investor sentiment was boosted by the promising results of its last clinical trial that tested the efficacy of its drug candidate for a type of stomach cancer called Gastrointestinal Stromal Tumors (GIST).

In an updated report, Cogent Biosciences, Inc. (NASDAQ:COGT) said it is set to file a new drug application with the Food and Drug Administration for its treatment candidate, bezuclastinib, in combination with sunitinib, after its phase 3 trial showed promising developments.

During the study, patients with Gastrointestinal Stromal Tumors (GIST) who took bezuclastinib in combination with sunitinib saw an average of 16.5 months without their cancer worsening, as compared with the 9.2 months for those who took sunitinib alone.

In addition, 46 percent of the patients who took the combo saw their tumors shrink, versus the 26 percent of patients who took sunitinib alone.

Cogent Biosciences, Inc. (NASDAQ:COGT) President and CEO Andrew Robbins said that the results surpassed the company’s expectations.“With these incredible results, including a greater than seven-month improvement on mPFS (median progression-free survival)—reducing the rate of progression or death by half—the bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients,” he said.

Following the results, Cogent Biosciences, Inc. (NASDAQ:COGT) announced plans to raise $200 million through the issuance of convertible senior notes due 2031, proceeds of which will be used to repay $50 million outstanding loans, with the remainder to be used to fund the development and regulatory activities for the expected launch and commercialization of bezuclastinib, alongside other drug candidates.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.